Contrasting Aclarion (NASDAQ:ACON) and Doximity (NYSE:DOCS)

Aclarion (NASDAQ:ACON) and Doximity (NYSE:DOCS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

7.5% of Aclarion shares are owned by institutional investors. Comparatively, 87.2% of Doximity shares are owned by institutional investors. 0.0% of Aclarion shares are owned by company insiders. Comparatively, 31.8% of Doximity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Aclarion has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Doximity has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Aclarion and Doximity, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	0	1	0	2.00
Doximity	4	12	7	2	2.28

Aclarion presently has a consensus price target of $7.50, suggesting a potential upside of 221.89%. Doximity has a consensus price target of $32.43, suggesting a potential upside of 22.54%. Given Aclarion’s higher possible upside, research analysts clearly believe Aclarion is more favorable than Doximity.

Valuation and Earnings

This table compares Aclarion and Doximity”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	83.88	-$7.23 million	($7.40)	-0.31
Doximity	$655.57 million	7.20	$196.05 million	$0.85	31.13

Doximity has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Doximity, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Aclarion and Doximity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,948.81%	-59.34%	-56.12%
Doximity	25.48%	18.06%	15.40%

Summary

Doximity beats Aclarion on 13 of the 15 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Doximity

Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company’s cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.